Topic: hospital-acquired infections (HAI)
One of the founding scientists of Illumina has come out with a new gene-sequencing software startup that aims to tackle antimicrobial resistance.
Aridis filed for a $34.5 million IPO as it plans to move its fully human antibodies for hospital-related infections into late-phase clinical trials.
A Tufts team has published research that explains how A. baumannii builds a protective coating, allowing it to evade destruction from antibiotics.
Ansun BioPharma raised $85 million in series A financing and plans to use the funds for an upcoming phase 3 trial of its DAS181 antiviral medication.
Here's this week's dose of medtech news of note.
Shares in Paratek Pharmaceuticals jumped 35% in premarket trading on the back of data from a phase 3 trial of its antibiotic candidate omadacycline.
Xenex Disinfection Services, which markets UV light-emitting, "germ-zapping" robots, picked up $38 million in a Series I round.